Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: $0.00 to $1.42
• 52-Week Range: $1.22 to $8.45
• Volume: 145 shs
• Average Volume: 29,344 shs
• Market Capitalization: $6,403.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NBRV Stock Analysis - Frequently Asked Questions

How have NBRV shares performed this year?

Nabriva Therapeutics' stock was trading at $0.0003 on January 1st, 2024. Since then, NBRV stock has decreased by 33.3% and is now trading at $0.0002.
View the best growth stocks for 2024 here.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.
Read the conference call transcript.

When did Nabriva Therapeutics' stock split?

Nabriva Therapeutics's stock reverse split on the morning of Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 5/06/2021
• Today: 11/10/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NBRV
• CUSIP: N/A
• CIK: 1641640
• Web: www.nabriva.com
• Phone: (531) 649-2000
• Fax: 610-816-6639
• Employees: 39
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($19.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,190,000.00
• Net Margins: -148.11%
• Pretax Margin: -144.78%
• Return on Equity: -365.53%
• Return on Assets: -135.81%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 0.85
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $35.59 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 32,015,000
• Free Float: 31,493,000
• Market Cap: $6,403.00
• Optionable: Not Optionable
• Beta: 1.53